Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada
Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 OXIGON�, the Company’s clinical-stage drug candidate that has disease-modifying potential for Alzheimer’s and other neurodegenerative disorders. OX1 is [...] http://bit.ly/cT2VHJ